August 15, 2016 / 10:12 AM / a year ago

BRIEF-Aurinia's Voclosporin meets primary endpoint

Aug 15 (Reuters) - Aurinia Pharmaceuticals Inc :

* Aurinia Pharmaceuticals announces voclosporin meets primary endpoint in phase IIB Aura-LV study in Lupus Nephritis

* Trial achieved its primary endpoint, demonstrating statistically significantly greater complete remission

* Plans to meet with U.S. FDA in q4 to discuss data and drug’s subsequent clinical development and path to registration in ln Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below